In addition, Gottlieb stressed, “Operations like CanaRx use their names to imply that patients are receiving medicines approved in Canada, when it’s likely that patients are receiving medicines from other countries, and which may be sub-potent, super-potent or counterfeit.”
Furthermore, Gottlieb is advising American employers and employees not to use any medicines obtained from CanaRx.
The FDA investigated CanaRx’s numerous websites, medication lists, and practices before issuing its warning letter. Its investigation into the Canadian company’s practices is ongoing.
